Citation
Neoadjuvant niraparib monotherapy for unresectable, homologous recombination deficiency-positive, high-grade serous ovarian cancer (NANT): a multicentre, single-arm, phase 2 trial. // The Lancet Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S1470204526003876?dgcid=rss_sd_all
Neoadjuvant niraparib monotherapy for unresectable, homologous recombination deficiency-positive, high-grade serous ovarian cancer (NANT): a multicentre, single-arm, phase 2 trial. The Lancet Oncology. https://www.sciencedirect.com/science/article/pii/S1470204526003876?dgcid=rss_sd_all
“Neoadjuvant niraparib monotherapy for unresectable, homologous recombination deficiency-positive, high-grade serous ovarian cancer (NANT): a multicentre, single-arm, phase 2 trial.” The Lancet Oncology.
@article{article68988,
title = {Neoadjuvant niraparib monotherapy for unresectable, homologous recombination deficiency-positive, high-grade serous ovarian cancer (NANT): a multicentre, single-arm, phase 2 trial},
journal = {The Lancet Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S1470204526003876?dgcid=rss_sd_all}
}